April 09, 2008
EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical ProgramApril 07, 2008
Dr. Ronald E. Cape to Retire from EntreMed Board of DirectorsApril 04, 2008
EntreMed Receives Nasdaq Deficiency NoticeApril 02, 2008
EntreMed Commences Continuous Dosing Clinical Trial For MKC-1March 25, 2008
EntreMed to Present at BioCentury Future Leaders in the Biotech Industry ConferenceMarch 13, 2008
EntreMed Announces 2008 Corporate and Clinical Program PrioritiesMarch 06, 2008
EntreMed Reports Fourth Quarter and Year-End 2007 Financial ResultsFebruary 26, 2008
EntreMed to Present at the Jesup & Lamont Emerging Growth Stock ConferenceFebruary 21, 2008
EntreMed to Present at the 7th Annual North America Forum for Investing and Partnering in BiotechFebruary 05, 2008
EntreMed to Present at BIO CEO and Investor ConferenceJanuary 27, 2008
EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor StudyJanuary 23, 2008
EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial CancersJanuary 03, 2008
EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-December 11, 2007
EntreMed Announces FDA Acceptance of IND Application for Panzem® in Rheumatoid ArthritisDecember 10, 2007
EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia ModelsDecember 10, 2007
EntreMed Presents Results for Its Lead Aurora Kinase-Angiogenesis InhibitorDecember 03, 2007
EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic CancerNovember 06, 2007
EntreMed Reports Third Quarter 2007 Financial ResultsOctober 31, 2007
EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare ConferenceOctober 25, 2007
EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
